

## Press Release

## Closing of the transaction for the divesture of Bikurofe Ltd., the Israeli outpatient clinics and doctor visit services, is completed.

Tel Aviv/Zurich, July 25, 2005 – SHL TeleMedicine Ltd. announces that the closing of the transaction announced earlier this months for the sale of Bikurofe Ltd., its Israeli outpatient clinics and doctor visit services, to IEL Israel Equity Ltd. for USD 14.7 million, has been completed.

As previously announced, SHL also received from Bikurofe payment of previously announced dividends and other debts in the amount of USD 4.3 million and will continue to render various services to Bikurofe for a total amount of USD 1.5 million.

SHL will record in the third quarter of 2005 a capital gain of around USD 9 million from the divesture.

The divesture of Bikurofe is in line with SHL's strategy to focus on its core telemedicine activities. Based on the recent progress of its international telemedicine operations, SHL is concentrating on the growth opportunities in Germany and the U.S.

\*\*\*

## About SHL TeleMedicine

SHL TeleMedicine Ltd. is a leading provider and developer of advanced personal telemedicine solutions as well as medical call center and diagnostic services to individuals and to the healthcare community. As a leading provider of remote health services in cardiology and in other medical areas, SHL maintains business operations in the US, Europe and Israel. SHL is listed on the SWX Swiss Exchange, symbol SHLTN. For more information please visit our web site on www.shl-telemedicine.com.

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, erez@shl-telemedicine.com
- Assistant: Pauline Shavit, Phone: +972 3561 22 12, pauline@shl-telemedicine.com
- Martin Meier-Pfister, The Investor Relations Firm AG, Phone: +41 43 244 81 40, shl@irfirm.biz